NCT06795113 Optimization of 18F-FDG PET/CT Response Assessment and Prognostic Evaluation Strategies for High-Metabolism Lymphoma
| NCT ID | NCT06795113 |
| Status | Recruiting |
| Phase | — |
| Sponsor | Ruijin Hospital |
| Condition | Lymphoma |
| Study Type | OBSERVATIONAL |
| Enrollment | 4,000 participants |
| Start Date | 2013-06-01 |
| Primary Completion | 2029-12-31 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
This is an observational study. You will not receive an experimental treatment; researchers will collect data based on your existing condition or standard treatment.
This trial targets 4,000 participants in total. It began in 2013-06-01 with a primary completion date of 2029-12-31.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
To develop a novel method for evaluating treatment response in lymphoma by utilizing PET/CT imaging data from patients with high-metabolic lymphoma. This involves comparing end-of-treatment PET (EOT-PET) with interim PET (iPET) results to establish a new response assessment approach. The aim is to contrast this method with the Lugano classification criteria, providing clinicians with more scientific and accurate tools for response evaluation and prognosis prediction.
Eligibility Criteria
Inclusion Criteria: 1. Histopathologically confirmed high-metabolic lymphoma 2. Underwent 18F-FDG PET/CT imaging before, during, and after treatment 3. Treated with a standard first-line therapeutic regimen according to lymphoma treatment guidelines and individualized patient-specific considerations 4. Complete clinicopathological and follow-up data available Exclusion Criteria 1: History of prior antitumor treatment 2: History of other malignancies 3: Incomplete clinical data or imaging records 4: Presence of other concurrent malignant tumors
Contact & Investigator
Frequently Asked Questions
Who can join the NCT06795113 clinical trial?
This trial is open to participants of all sexes, aged 18 Years or older, up to 100 Years, studying Lymphoma. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT06795113 currently recruiting?
Yes, NCT06795113 is actively recruiting participants. Contact the research team at gr11734@rjh.com.cn for enrollment information.
Where is the NCT06795113 trial being conducted?
This trial is being conducted at Shanghai, China.
Who is sponsoring the NCT06795113 clinical trial?
NCT06795113 is sponsored by Ruijin Hospital. The trial plans to enroll 4,000 participants.